HIV 感染者的血脂异常与血脂管理。
Dyslipidemia and lipid management in HIV-infected patients.
机构信息
Department of Medicine, Harvard Medical School, Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
出版信息
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
Abstract
PURPOSE OF REVIEW
Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.
RECENT FINDINGS
Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
SUMMARY
Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.
摘要
目的综述
血脂异常在慢性 HIV 感染患者中非常普遍，可能会增加该患者人群患心血管疾病的风险。本综述总结了最近研究 HIV 感染患者中脂质异常及其管理的相关数据。
最近的发现
过去一年的研究评估了各种降脂治疗药物的作用，这些药物以前并未在 HIV 患者人群中进行过研究。瑞舒伐他汀是一种强效他汀类药物，似乎在患有高胆固醇血症的 HIV 感染患者中耐受性良好且有效。
总结
血脂异常在 HIV 感染者中很常见。治疗血脂异常的药物治疗需要考虑降脂药物和抗逆转录病毒药物之间潜在的药物相互作用。
相似文献
1
Dyslipidemia and lipid management in HIV-infected patients.
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
2
Lipid management in patients who have HIV and are receiving HIV therapy.
Endocrinol Metab Clin North Am. 2009 Mar;38(1):207-22. doi: 10.1016/j.ecl.2008.11.009.
3
Clinical management considerations for dyslipidemia in HIV-infected individuals.
Postgrad Med. 2012 Jan;124(1):31-40. doi: 10.3810/pgm.2012.01.2515.
4
Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):995-1004. doi: 10.1517/17425255.2010.504715.
5
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125.
6
Management of lipid disorders in patients living with HIV.
J Clin Pharmacol. 2015 Sep;55(9):957-74. doi: 10.1002/jcph.473. Epub 2015 Jun 23.
7
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Ann Intern Med. 2009 Mar 3;150(5):301-13. doi: 10.7326/0003-4819-150-5-200903030-00006.
8
Lipid metabolism in treated HIV Infection.
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429-42. doi: 10.1016/j.beem.2011.04.004.
9
Dyslipidemia in HIV-infected individuals.
Braz J Infect Dis. 2010 Nov-Dec;14(6):575-88. doi: 10.1016/s1413-8670(10)70115-x.
10
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Pharmacotherapy. 2008 Jul;28(7):932-8. doi: 10.1592/phco.28.7.932.
引用本文的文献
1
Pathogenesis of HIV-Associated Metabolic Syndrome and Clinical Management Recommendations.
Int J Gen Med. 2025 Sep 9;18:5213-5232. doi: 10.2147/IJGM.S528870. eCollection 2025.
2
Metabolic dysfunction-associated steatotic liver disease in people with HIV.
Curr Opin HIV AIDS. 2025 Jul 1;20(4):350-358. doi: 10.1097/COH.0000000000000952. Epub 2025 May 21.
3
Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review.
Health Sci Rep. 2025 Apr 18;8(4):e70727. doi: 10.1002/hsr2.70727. eCollection 2025 Apr.
4
PVAT adipocyte: energizing, modulating, and structuring vascular function during normotensive and hypertensive states.
Am J Physiol Heart Circ Physiol. 2025 Jun 1;328(6):H1204-H1217. doi: 10.1152/ajpheart.00093.2025. Epub 2025 Apr 18.
5
Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.
Int J Mol Sci. 2025 Jan 22;26(3):914. doi: 10.3390/ijms26030914.
6
HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps.
Circ Res. 2024 May 24;134(11):e150-e175. doi: 10.1161/CIRCRESAHA.124.323979. Epub 2024 May 23.
7
Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0166823. doi: 10.1128/aac.01668-23. Epub 2024 Mar 14.
8
Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.
Infect Chemother. 2022 Jun;54(2):220-235. doi: 10.3947/ic.2022.0061. Epub 2022 May 31.
9
Metabolic Consequences of Antiretroviral Therapy.
Curr HIV/AIDS Rep. 2022 Apr;19(2):141-153. doi: 10.1007/s11904-022-00600-6. Epub 2022 Mar 17.
10
Spectrum of Dyslipidemias in Treatment-Naïve Human Immunodeficiency Virus-Infected Patients Presenting to an HIV Clinic of a Tertiary Care Hospital.
Cureus. 2022 Feb 7;14(2):e21972. doi: 10.7759/cureus.21972. eCollection 2022 Feb.
本文引用的文献
1
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.
J Acquir Immune Defic Syndr. 2010 Sep;55(1):82-6. doi: 10.1097/QAI.0b013e3181d9a354.
2
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.
AIDS. 2010 Apr 24;24(7):1019-23. doi: 10.1097/QAD.0b013e3283383016.
3
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.
AIDS. 2010 Jan 16;24(2):243-53. doi: 10.1097/QAD.0b013e328333ea9e.
4
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.
AIDS. 2010 Jan 2;24(1):77-83. doi: 10.1097/QAD.0b013e328331d2ab.
5
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.
Atherosclerosis. 2009 Dec;207(2):524-9. doi: 10.1016/j.atherosclerosis.2009.05.001. Epub 2009 May 13.
6
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.
Ann Intern Med. 2009 Mar 3;150(5):301-13. doi: 10.7326/0003-4819-150-5-200903030-00006.
7
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.
Clin Infect Dis. 2008 Oct 15;47(8):1105-8. doi: 10.1086/592116.
8
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.
AIDS. 2007 Nov 30;21(18):2543-6. doi: 10.1097/QAD.0b013e3282f25123.
9
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):459-66. doi: 10.1097/QAI.0b013e31815bace2.
10
Increased carotid intima media thickness and cardiac biomarkers in HIV infected children.
AIDS. 2007 May 11;21(8):921-7. doi: 10.1097/QAD.0b013e328133f29c.
Zotero 插件